591. Deputy Ken O'Flynn asked the Minister for Health the total expenditure incurred in 2024 and 2025 on salbutamol nebules and equivalent substitute products under the Community Drug Schemes; the additional expenditure, if any, arising from the use of Exempt Medicinal Products during shortage periods; and the budgetary provisions in place to manage future supply disruptions. [13632/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
604. Deputy Ken O'Flynn asked the Minister for Health whether there is a formal departmental policy providing for automatic reimbursement of clinically equivalent substitute medicines once the Health Products Regulatory Authority has listed a reimbursable product as being in shortage; if not, whether she will outline the policy rationale for the absence of such an automatic trigger mechanism; and whether consideratio…
605. Deputy Ken O'Flynn asked the Minister for Health to set out the statutory, regulatory, or administrative basis under which Exempt Medicinal Products are supported under Discretionary Hardship Arrangements during medicine shortages; whether these arrangements are governed by published criteria; and whether her Department intends to place such arrangements on a formalised national footing. [13654/26]
607. Deputy Ken O'Flynn asked the Minister for Health whether national clinical governance guidance has been issued by her Department or by the HSE in respect of reimbursement decision-making during shortages of time-sensitive respiratory medicines, including salbutamol nebules; whether such guidance addresses continuity of care, risk mitigation, and equity of access; and if she will make a statement on the matter. […
608. Deputy Ken O'Flynn asked the Minister for Health the number of occasions in the past three years on which medicines listed on the Community Drug Schemes Reimbursement List were formally declared in shortage by the Health Products Regulatory Authority; in how many such cases substitute reimbursement required discretionary approval; and whether her Department maintains a central register of such occurrences. [1365…
611. Deputy Ken O'Flynn asked the Minister for Health whether her Department has engaged with representative bodies for community pharmacists, respiratory clinicians, or patient advocacy groups in relation to reimbursement continuity during medicine shortages; whether any formal consultation process has been undertaken since 2020; and if she will provide details of the outcome of any such engagement. [13660/26]
612. Deputy Ken O'Flynn asked the Minister for Health whether she will commit to publishing a formal contingency reimbursement protocol setting out clear, automatic procedures for substitute medicine reimbursement where a reimbursable product is listed in shortage by the Health Products Regulatory Authority; and if she will indicate a timeframe for the development and publication of such a protocol. [13661/26]
636. Deputy Ken O'Flynn asked the Minister for Health the current number of medicines listed as being in short supply on the national medicines shortage list maintained by the Health Products Regulatory Authority; the number of these classified as critical or without a clinically equivalent alternative; the average duration of shortages recorded in each of the past three years; and the steps being taken at Department…
637. Deputy Ken O'Flynn asked the Minister for Health whether her Department maintains a formal medicines supply resilience strategy addressing strategic stockholding, diversification of supply chains, early warning mechanisms and substitution protocols; if so, when it was last reviewed; and if she will outline the key policy measures currently in force [13763/26]
638. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives routine structured reports from the Health Products Regulatory Authority and the HSE regarding medicines shortages affecting chronic disease management, including respiratory conditions; the frequency and format of such reports; and how this information informs policy and budgetary planning [13764/26]
639. Deputy Ken O'Flynn asked the Minister for Health whether automatic reimbursement mechanisms are in place under community drug schemes to ensure that where a reimbursable medicine is unavailable due to shortage, clinically appropriate substitute medicines are reimbursed without additional administrative burden on patients or prescribers; and if not, whether she will introduce such a mechanism [13765/26]
640. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any assessment of the patient safety, treatment interruption or cost implications arising from medicines shortages in the past three years; if so, the findings of that assessment; and if not, whether such an assessment will now be commissioned [13766/26]
641. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued formal policy guidance to the Health Service Executive or to the National Centre for Pharmacoeconomics regarding the appropriate time horizon to be applied in health technology assessments where medicines are intended to reduce the long-term incidence of chronic diseases such as type 2 diabetes and cardiovascular disease; and if s…
672. Deputy Pádraig Rice asked the Minister for Health the number of people on a waiting list for pre-exposure prophylaxis, by clinic; and the wait time to be offered a new appointment in each clinic, in tabular form. [13935/26]
673. Deputy Pádraig Rice asked the Minister for Health to list all public pre-exposure prophylaxis clinics; and to identify the sites in which waiting lists are closed to new self-referrals, in tabular form. [13936/26]
674. Deputy Pádraig Rice asked the Minister for Health the funding allocated to public pre-exposure prophylaxis services to expand capacity, reduce waiting lists and ensure that the waiting lists in all public clinics are open to new self-referrals; and if she will make a statement on the matter. [13937/26]
675. Deputy Pádraig Rice asked the Minister for Health if a new model of pre-exposure prophylaxis will be considered, given the strain on existing clinics (details supplied); if she will review this model; and if she will make a statement on the matter. [13938/26]
280. Deputy Marie Sherlock asked the Minister for Health the reason that preservative-free cosopt eye drops have not been made available on the drugs payment scheme given that it is being prescribed to patients in Ireland; the reason that the licence for preservative-free cosopt drops was withdrawn by the Health Products Regulatory Authority; and if she will make a statement on the matter. [13130/26]
287. Deputy Liam Quaide asked the Minister for Health her plans to add Acarizax to the reimbursement list; and if she will make a statement on the matter. [13176/26]
1078. Deputy Conor D. McGuinness asked the Minister for Health the steps her Department is taking to ensure that the price of mounjaro is consistent across all outlets, does not vary widely depending on the outlet which the patient seeks it from, and that the cost of this medicine is not a barrier to those patients for whom it is a necessity; and if she will make a statement on the matter. [11772/26]
575. Deputy David Cullinane asked the Minister for Health her views on matters raised in correspondence (details supplied); if the bexcero vaccine has been examined and will be made available through such clinics; and if she will make a statement on the matter. [11338/26]
608. Deputy Peter 'Chap' Cleere asked the Minister for Health if the medicine skyclaris/ omaveloxalone will be reimbursed by the HSE as it is the only drug approved to treat Freidreicsh’s ataxia; and if she will make a statement on the matter. [11491/26]
309. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to welireg (belzutifan) for a young adult with von Hippel-Lindau disease in County Kildare (details supplied) where clinicians advise that delay risks irreversible loss of neurological and functional ability; and if she will make a statement on the matter. [10622/26]
315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each …
316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstrea…